Company intelligence
Helio Genomics
At Helio, we focus on detecting cancer early —when it is most treatable—so everyone can have the best chance to beat it.
About Helio Genomics
Helio Genomics is a commercial-stage AI-powered precision cancer detection company focused on improving outcomes through early cancer detection, disease surveillance, and biomarker-driven precision medicine. Our mission is simple: save lives by detecting cancer earlier, when treatment options are greatest and outcomes can be improved. Through our proprietary multi-modal and multi-omics platform, we develop innovative blood-based technologies designed to help identify cancer earlier and support better clinical decision-making. Our flagship product, HelioLiver®, is a blood-based test designed to improve surveillance and early detection of hepatocellular carcinoma (HCC) in patients at risk for liver cancer. Headquartered in the United States, Helio Genomics collaborates with leading physicians, scientists, healthcare organizations, and research institutions to advance the future of cancer detection and precision medicine. Helio Genomics operates CLIA- and CAP-certified laboratory facilities and is committed to bringing clinically meaningful innovations to patients and providers worldwide.
Verified activity
Signals from Helio Genomics
1 published signal